Description
Seeking men and women aged 12 and older with cystic fibrosis of specific genotypes for a study of whether adding an investigational drug to elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) treatment improves lung function.
Overview
Participants in this study will be randomly assigned to either the study drug or placebo (looks like the investigational drug but contains no medication) in combination with elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) treatment. There are up to 20 study visits over 64 weeks that range in duration from 30 minutes to 8.5 hours.
What we're hoping for
We are studying whether adding an investigational drug to elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) treatment for cystic fibrosis improves lung function over ELX/TEZ/IVA treatment alone.
Additional Information
ClinicalTrials.gov Identifier: NCT05076149